Clinical trials of germline gene editing: The exploitation problem
By Erik Malmqvist,
Bioethics
| 06. 14. 2021
Abstract
The birth of the world’s first genetically edited babies in 2018 provoked considerable ethical outrage. Nonetheless, many scientists and bioethicists now advocate the pursuit of clinical uses of human germline gene editing. Progress towards this goal will require research, including clinical trials where genetically edited embryos are implanted into a woman’s uterus, gestated, and brought to term. This paper argues that such trials would likely conflict with the fundamental research ethical requirement of non-exploitation. This is because they would expose people who are in a vulnerable situation to risks and burdens that are substantial and not obviously offset by compensating benefits. I consider how the potential for exploitation in such trials might be mitigated, arguing that a feasible and justifiable approach is not easily found. If this analysis is correct, there is a significant ethical obstacle on the path towards clinical use of human germline gene editing.
1 INTRODUCTION
In late 2018, He Jankui announced the birth of Lulu and Nana, the world’s first human beings born with an edited genome.1 The Chinese scientist had used the novel...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Elise Kinsella, ABC News | 06.15.2025
When *Sarah and her partner needed fertility testing, it was Monash IVF that the pair turned to.
"Having a quick browse online, Monash IVF was one of the most prominent ones that came up on Google search and after contacting...
By Tory Shepherd, The Guardian | 06.13.2025
IVF is “big business” and experts are concerned about conflicts of interest between profit-making and helping families have children.
Monash IVF’s second embryo bungle has sparked renewed scrutiny on the IVF industry as a whole amid calls for national regulation...